ATXN2 gene therapy (HuidaGene Therapeutics/Chinese Academy of Sciences)

N/A

Report date: 2025/06/11 11:02:28

Base Information

Drug NameATXN2 gene therapy (HuidaGene Therapeutics/Chinese Academy of Sciences)
Drug Alias NameAAV-hfCas12Max-gATXN2
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionAtaxin-2 stimulantsNeuroprotectants
TargetsAtaxin-2
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHuidaGene Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuidaGene Therapeutics Co LtdChinese Academy Of Sciences
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A